Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA-7×19 CAR-T cells
- Development stage
- Approved
- Lead developer
- Tongji Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BCMA-7×19 CAR-T cells are a fourth-generation chimeric antigen receptor T cell therapy engineered to target B-cell maturation antigen (BCMA) on malignant plasma cells, while simultaneously secreting interleukin-7 (IL-7) and chemokine CCL19 to enhance in vivo proliferation, migration, and persistence of CAR-T cells. This modification aims to overcome relapse rates and promote deeper and more durable responses in patients with relapsed or refractory multiple myeloma by improving CAR-T cell functionality and tumor microenvironment modulation. In early-phase clinical studies, BCMA-7×19 CAR-T cells showed promising safety and efficacy, with manageable cytokine release syndrome and durable remissions observed[1][2].
- Brand names
- Humulin RHumulin R U-100
- Other names
- 4th generation chimeric antigen receptor T-cells7×19 CAR-T cellsIL-7 and CCL19-expressing CAR-T cellsIL7 and CCL19-expressing CAR-T cellsIL 7 and CCL19-expressing CAR-T cells
02
Targets
CCR7 (C-C Motif Chemokine Receptor 7)IL7R (Interleukin-7 Receptor)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on BCMA-7×19 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA-7×19 CAR-T cells.